Methylphenidate
- Generic Name
- Methylphenidate
- Brand Names
- Adhansia, Aptensio, Biphentin, Concerta, Cotempla, Daytrana, Foquest, Jornay, Metadate, Methylin, Quillichew, Quillivant, Relexxii, Ritalin
- Drug Type
- Small Molecule
- Chemical Formula
- C14H19NO2
- CAS Number
- 113-45-1
- Unique Ingredient Identifier
- 207ZZ9QZ49
- Background
Methylphenidate is a central nervous system stimulant used most commonly in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and for narcolepsy. Also known as the marketed products Ritalin, Concerta, or Biphentin, methylphenidate is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve ...
- Indication
Methylphenidate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older and for the treatment of narcolepsy.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Narcolepsy
- Associated Therapies
- -
Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 30
- Registration Number
- NCT04781972
- Locations
- 🇺🇸
Johns Hopkins School of Medicine, Baltimore, Maryland, United States
Evaluation of the Effect Foquest® on Sleep in Children Aged 6-12 With ADHD
- Conditions
- Interventions
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- JPM van Stralen Medicine Professional
- Target Recruit Count
- 41
- Registration Number
- NCT04741516
- Locations
- 🇨🇦
Center for Pediatric Excellence, Ottawa, Ontario, Canada
Effects of Methylphenidate on Brain and Cognition in 22q11 Deletion Syndrome
- First Posted Date
- 2020-12-01
- Last Posted Date
- 2022-10-07
- Lead Sponsor
- University of Geneva, Switzerland
- Target Recruit Count
- 45
- Registration Number
- NCT04647500
- Locations
- 🇨🇭
Developmental imaging and psychopathology lab, Geneva, Switzerland
Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)
- Conditions
- Interventions
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 267
- Registration Number
- NCT04507204
- Locations
- 🇺🇸
Neurobehavioral Medicine Group, Bloomfield Hills, Michigan, United States
🇺🇸InSite Clinical Research, LLC, DeSoto, Texas, United States
🇺🇸Rochester Center for Behavioral Medicine, Rochester Hills, Michigan, United States
Precision Functional Brain Mapping in Psilocybin
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 11
- Registration Number
- NCT04501653
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder
- Conditions
- Interventions
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Donald Gilbert, MD, MS, FAAN, FAAP
- Target Recruit Count
- 214
- Registration Number
- NCT04421248
- Locations
- 🇺🇸
Kennedy Krieger Institute, Baltimore, Maryland, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 226
- Registration Number
- NCT04419272
- Locations
- 🇺🇸
Miami VA Healthcare System, Miami, FL, Miami, Florida, United States
🇺🇸Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY, New York, New York, United States
🇺🇸VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States
Studying the Role of Brain Molecules for Decision Making
- Conditions
- Interventions
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 160
- Registration Number
- NCT04384562
- Locations
- 🇨🇭
University of Zurich, Zurich, Switzerland
The Role of Dopaminergic and Noradrenergic Neurotransmission in Value- and Salience-based Decision-Making
- Conditions
- Interventions
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 120
- Registration Number
- NCT04371146
- Locations
- 🇨🇭
University of Zurich, Zurich, Switzerland
The Relationship Between CES1 Genotype and Methylphenidate Response in Children With ADHD - INDICES Work Package 6
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2020-04-29
- Target Recruit Count
- 207
- Registration Number
- NCT04366609
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.